Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + lenalidomide versus rituximab maintenance after R-chemotherapy in relapsed/refractory follicular lymphoma
2024-511640-11-00Phase 3Authorised
- Sponsor
- Fondazione Italiana Linfomi
- Start
- May 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in follicular lymphoma (FL) comparing Lenalidomide + rituximab maintenance with Rituximab maintenance (2 arms). Primary endpoint: Progression-free survival. Planned start May 2014; status: authorised.
02
Drugs
lenalidomiderituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2024-511640-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511640-11-00.